Comments
Drug firm Hikal Ltd today said its manufacturing facility in Gujarat has received approval from the US Food and Drug Administration (USFDA).
“Our second facility located in Bharuch district of Gujarat...manufactriung pharmaceutical ingredients, intermediates has successfully completed a USFDA audit and received approval,” Hikal said in a filing to the BSE.
The company has already received USFDA approval for its facility in Bangalore, it added.
“The additional site approval will further add to capacities, which is beneficial to our customers. It will mitigate the risk of supply by having two sites certified by the USFDA,” the company said.
Both the sites have multipurpose facilities and capabilities which support Hikal’s global customers, it added.
Hikal scrip closed at Rs 396.75 on the BSE, down 1 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.